DVA vs UNCY
DVA: Leading US dialysis and integrated kidney care provider serving end-stage renal disease patients across clinical centers, home-based settings, and transplant support globally. UNCY: A clinical-stage biotechnology firm developing nanoparticle-based and novel therapies to address significant unmet medical needs in kidney disease.
Side-by-side fundamentals
| Metric | DVA | UNCY | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $232.08 | $5.57 | |
| Market cap as of 2026-07-23 | $15.0B | $149M | |
| P/E as of 2026-07-23 | 19.22 | n/a | |
| PEG as of 2026-07-23 | 7.29 | -9.62 | UNCY lower |
| Net margin as of 2026-07-23 | +5.7% | -4159.1% | DVA higher |
| Gross margin as of 2026-07-23 | +32.5% | n/a | |
| Operating margin as of 2026-07-23 | +15.0% | -2931.4% | DVA higher |
| ROE as of 2026-07-23 | +181.2% | -131.2% | DVA higher |
| ROA as of 2026-07-23 | +4.5% | -82.3% | DVA higher |
| Debt / equity as of 2026-07-23 | 77.99 | 0.00 | UNCY lower |
| Revenue growth (YoY) as of 2026-07-23 | +6.7% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +5.5% | n/a | |
| Beta as of 2026-07-23 | 0.88 | 1.72 | |
| 1-year return as of 2026-07-22 close | +58.9% | +26.4% | DVA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.